AU4430689A - Sustained release drug-resin complexes - Google Patents

Sustained release drug-resin complexes

Info

Publication number
AU4430689A
AU4430689A AU44306/89A AU4430689A AU4430689A AU 4430689 A AU4430689 A AU 4430689A AU 44306/89 A AU44306/89 A AU 44306/89A AU 4430689 A AU4430689 A AU 4430689A AU 4430689 A AU4430689 A AU 4430689A
Authority
AU
Australia
Prior art keywords
drug
sustained release
release drug
resin complexes
resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU44306/89A
Other versions
AU638420B2 (en
Inventor
Anthony Earl Carpanzano
William Joseph Kelleher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richardson Vicks Inc
Original Assignee
Richardson Vicks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richardson Vicks Inc filed Critical Richardson Vicks Inc
Publication of AU4430689A publication Critical patent/AU4430689A/en
Application granted granted Critical
Publication of AU638420B2 publication Critical patent/AU638420B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Disclosed are oral pharmaceutical preparations which comprise a pharmacologically active drug bound to small particles of an ion-exchange resin to provide a drug-resin complex having a drug content above a specified value. The drug-resin complex is subsequently coated with a water-permeable diffusion barrier coating that is insoluble in gastrointestinal fluids thereby providing a controllable sustained release of drug under conditions encountered in the gastrointestinal tract.
AU44306/89A 1988-11-02 1989-11-01 Sustained release drug-resin complexes Ceased AU638420B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/265,910 US4996047A (en) 1988-11-02 1988-11-02 Sustained release drug-resin complexes
US265910 1988-11-02

Publications (2)

Publication Number Publication Date
AU4430689A true AU4430689A (en) 1990-05-10
AU638420B2 AU638420B2 (en) 1993-07-01

Family

ID=23012384

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44306/89A Ceased AU638420B2 (en) 1988-11-02 1989-11-01 Sustained release drug-resin complexes

Country Status (11)

Country Link
US (1) US4996047A (en)
EP (1) EP0367746B1 (en)
JP (1) JP2941314B2 (en)
AT (1) ATE101033T1 (en)
AU (1) AU638420B2 (en)
CA (1) CA2001859C (en)
DE (1) DE68912882T2 (en)
DK (1) DK175659B1 (en)
IE (1) IE62765B1 (en)
NZ (1) NZ231229A (en)
PH (1) PH26699A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013798A1 (en) * 1993-11-18 1995-05-26 Cancer Research Institute Inc. Controlled release preparation

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005498D0 (en) * 1990-03-12 1990-05-09 Beecham Group Plc Composition
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
EP0563294A1 (en) * 1990-12-21 1993-10-06 Richardson-Vicks, Inc. Polyamine drug-resin complexes
US5275820A (en) * 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
IT1250736B (en) * 1991-08-01 1995-04-21 Zambon Spa PROCESS FOR PREPARATION OF SALICYLIC 5- (2 ', 4'-DIFLUOROFENYL) ACID IN PURE FORM
SE9103110D0 (en) 1991-10-24 1991-10-24 Kabi Pharmacia Ab NEW DRUG FORMULATION
US5492700A (en) * 1991-11-26 1996-02-20 Warner-Lambert Company Process and composition for the development of controlled release gemfibrozil dosage form
IT1252185B (en) * 1991-12-11 1995-06-05 Therapicon Srl PROGRAMMED LIBERATION PHARMACEUTICAL PREPARATIONS
US5260066A (en) * 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
CA2063499C (en) * 1992-03-19 1996-06-18 Leon Edward St. Pierre Ingestible polymeric phosphonium salts for the lowering of blood cholesterol
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
JP3278192B2 (en) * 1992-04-03 2002-04-30 ロート製薬株式会社 Sustained release liquid
TW237386B (en) * 1992-04-15 1995-01-01 Ciba Geigy
SE9202250D0 (en) * 1992-07-29 1992-07-29 Gacell Lab Ab CONTROLLED RELEASE MORPHINE PREPARATION
ATE198277T1 (en) * 1992-10-02 2001-01-15 Genetics Inst COMPOSITION INCLUDING COAGULATION FACTOR VIII; METHOD FOR THE PRODUCTION THEREOF AND THE USE OF A SURFACE-ACTIVE SUBSTANCE AS A STABILIZER
DK0667148T3 (en) * 1992-11-06 2002-07-22 Hisamitsu Pharmaceutical Co Oral pharmaceutical composition that is triggered in the lower gastrointestinal tract
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
ATE181672T1 (en) * 1993-04-28 1999-07-15 Takeda Chemical Industries Ltd FLAVOR-MASKED SOLID PREPARATION AND METHOD FOR PRODUCING
ZA944949B (en) * 1993-07-12 1995-04-05 Smithkline Beecham Corp Matrix-entrapped beadlet preparation
EP0664699A1 (en) * 1993-08-13 1995-08-02 Vitaphore Corporation Hydrogel-based microsphere drug delivery systems
DE4402379C2 (en) * 1994-01-27 1997-09-25 Lohmann Therapie Syst Lts Oral dosage form with acidic active ingredients and process for their preparation
US6322815B1 (en) 1994-07-22 2001-11-27 W. Mark Saltzman Multipart drug delivery system
US6491945B1 (en) * 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US6413539B1 (en) * 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
GB9607955D0 (en) * 1996-04-17 1996-06-19 Tillotts Pharma Ag Hydrophobic carbomer salt compositions
PT946145E (en) * 1996-12-20 2008-10-17 Mcneil Ppc Inc Antitussive drugs delivered by ion exchange resins
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
WO2000040224A1 (en) * 1999-01-07 2000-07-13 Elan Corporation, Plc Multiparticulate oral dosage forms
JP2003504416A (en) * 1999-07-14 2003-02-04 シェーリング−プラウ・リミテッド Taste masking of oral quinolone liquid formulations using ion exchange resins
ES2374717T3 (en) 1999-10-29 2012-02-21 Euro-Celtique S.A. FORMULATIONS OF CONTROLLED RELEASE HYDROCODONE.
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7067116B1 (en) * 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US6855721B1 (en) 2000-07-28 2005-02-15 Indevus Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
JP2004512354A (en) 2000-10-30 2004-04-22 ユーロ−セルティーク，エス．エイ． Hydrocodone controlled release formulation
AU2002220248A1 (en) * 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
EP1383376A4 (en) * 2001-03-19 2006-03-08 Praecis Pharm Inc Pharmaceutical formulations for sustained release
US20060198815A1 (en) * 2001-03-19 2006-09-07 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
US6623754B2 (en) * 2001-05-21 2003-09-23 Noveon Ip Holdings Corp. Dosage form of N-acetyl cysteine
US20030099711A1 (en) * 2001-08-29 2003-05-29 David Meadows Sustained release preparations
US20040242632A1 (en) * 2001-11-09 2004-12-02 Charous B. Lauren Method for treating inflammatory bowel disease
MXPA04009701A (en) * 2002-04-05 2005-05-27 Penwest Pharmaceuticals Co Sustained release metoprolol formulations.
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
CA2498798A1 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
CA2509429A1 (en) 2002-11-26 2004-06-10 University Of Maryland, Baltimore Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
JP2006515008A (en) * 2003-01-28 2006-05-18 コレギウム ファーマシューティカル， インコーポレイテッド Multiparticulate composition of milnacipran for oral administration
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
WO2005013934A2 (en) * 2003-07-28 2005-02-17 Novartis Consumer Health S.A. Taste-masked composition of cationic exchange resin
EP1667658A2 (en) * 2003-09-03 2006-06-14 Mallinckrodt Inc. Granular sustained release preparation and production thereof
KR20060092255A (en) 2003-09-26 2006-08-22 알자 코포레이션 Drug coating providing high drug loading and methods for providing the same
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20050142097A1 (en) * 2003-12-29 2005-06-30 Deepak Thassu Multiple active drug resin conjugate
US20070232695A1 (en) * 2004-01-28 2007-10-04 Collegium Pharmaceutical, Inc. Gelled Periodontal Anesthetic Preparation
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20050226920A1 (en) * 2004-04-13 2005-10-13 Kirk Voelker Method of decreasing nicotine withdrawal symptoms during smoking cessation.
AU2005237607B2 (en) 2004-04-27 2010-12-16 Medicinova, Inc. Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases
EP1750710B1 (en) * 2004-05-14 2014-04-16 KNU-Industry Cooperation Foundation Neuroprotective properties of dextrorotatory morphinans
WO2005115336A2 (en) * 2004-05-15 2005-12-08 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US9308164B2 (en) * 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
WO2006101536A1 (en) * 2004-11-04 2006-09-28 Akina, Inc. Fast-melting tablets having taste-masking and sustained release properties
EP1846040A2 (en) * 2005-01-28 2007-10-24 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
EP2361612A3 (en) * 2005-06-09 2011-10-12 Upm Pharmaceuticals, Inc. Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
JP2008546835A (en) * 2005-06-28 2008-12-25 ユ セ ベ ソシエテ アノニム Multiple active drug-resin conjugates
US8343546B2 (en) * 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
EP1926736A4 (en) * 2005-09-21 2010-08-25 Chong Kun Dang Pharm Corp Novel resinate complex of s-clopidogrel and production method thereof
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
CA2645855C (en) * 2006-03-16 2015-02-03 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US20080044462A1 (en) * 2006-04-06 2008-02-21 Collegium Pharmaceutical, Inc. Delaware Stabilized transdermal bupropion preparations
US20070286903A1 (en) * 2006-06-13 2007-12-13 Becicka Brian T Composition and method for taste masking
US20080064694A1 (en) * 2006-09-11 2008-03-13 Auriga Laboratories, Inc. Multi-Phase Release Methscopolamine Compositions
WO2008033155A1 (en) * 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for prevention and treatment of rhinitis
US20080085312A1 (en) * 2006-10-04 2008-04-10 Auriga Laboratories, Inc. Multi-Phase Release Potassium Guaiacolsulfonate Compositions
EP2120945A1 (en) * 2007-02-28 2009-11-25 Collegium Pharmaceutical, Inc. Antihistamine combination
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
EP2187873B1 (en) * 2007-08-13 2018-07-25 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
WO2010034344A1 (en) * 2008-09-24 2010-04-01 Evonik Röhm Gmbh Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol
WO2010133961A1 (en) 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
AU2010337856A1 (en) * 2009-12-31 2012-07-19 Ranbaxy Laboratories Limited Taste masked dosage forms of bitter tasting anti-retroviral drugs
US8470375B1 (en) 2010-01-05 2013-06-25 Neos Therapeutics, Lp Method of formulating and designing liquid drug suspensions containing ion exchange resin particles
WO2012042314A1 (en) 2010-10-02 2012-04-05 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US20130230587A1 (en) 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
EP2726066B1 (en) 2011-06-28 2021-03-31 Neos Therapeutics, LP Dosage forms of amphetamine for oral administration
WO2013070656A1 (en) * 2011-11-07 2013-05-16 Navinta Llc Sustained release suspension preparation for dextromethorphan
US8835499B2 (en) 2011-12-08 2014-09-16 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis
US8962687B2 (en) 2012-12-05 2015-02-24 Medicinova, Inc. Method of treating liver disorders
WO2013084090A1 (en) 2011-12-09 2013-06-13 Wockhardt Limited Oral liquid concentrate comprising brompheniramine, pseudoephedrine and dextromethorphan
US20150056288A1 (en) * 2011-12-14 2015-02-26 Wockhardt Limited Modified release liquid pharmaceutical composition comprising bromopheniramine, pseudoephedrine and dextromethorphan
BR112015003120B1 (en) 2012-08-15 2022-08-09 Tris Pharma , Inc METHYLPHENIDATE EXTENDED RELEASE CHEW TABLET AND ITS USE
WO2014111955A1 (en) * 2013-01-15 2014-07-24 Sun Pharmaceutical Industries Ltd. Fingolimod containing stable composition
US20140275038A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
WO2015013395A1 (en) 2013-07-25 2015-01-29 Medicinova, Inc. Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015076821A1 (en) * 2013-11-22 2015-05-28 Tris Pharma, Inc. Novel clonidine formulation
US20150321989A1 (en) 2014-05-08 2015-11-12 Medicinova, Inc. Method of treating idiopathic pulmonary fibrosis
US9346754B2 (en) 2014-05-08 2016-05-24 Medicinova, Inc. Method of treating advanced non-alcoholic steatohepatitis
JP6469727B2 (en) 2014-06-02 2019-02-13 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． Method for inhibiting or treating fibrosis
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
ES2891306T3 (en) 2014-11-26 2022-01-27 Medicinova Inc Combination of ibudilast and riluzole and methods of using them
MA41152A (en) * 2014-12-12 2017-10-17 Johnson & Johnson Consumer Inc PROCESS FOR MANUFACTURING PARTICLES OF PHENYLEPHRINE RESINATE; PHENYLEPHRINE RESINATE PARTICLES AND USE OF PHENYLEPHRINE RESINATE PARTICLES IN PHARMACEUTICAL FORMULATIONS
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
CA3034895A1 (en) 2016-08-26 2018-03-01 Exciva Ug (Haftungsbeschrankt) Compositions and methods thereof
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
JP2021506984A (en) 2017-12-18 2021-02-22 トリス・フアルマ・インコーポレーテツド Release-regulated drug powder composition comprising a gastric retention RAFT formation system with trigger pulse drug release
CA3085941A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2019126325A1 (en) * 2017-12-22 2019-06-27 Dow Global Technologies, Llc Pharmaceutical composition containing crosslinked ion exchange resin
WO2019126321A1 (en) * 2017-12-22 2019-06-27 Dow Global Technologies, Llc Pharmaceutical composition containing resin particles
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition
CA3217719A1 (en) 2021-05-28 2022-12-01 Kazuko Matsuda Phenoxyalkylcarboxylic acid derivatives and their use in lowering triglyceride levels

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990332A (en) * 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US3138525A (en) * 1961-06-16 1964-06-23 Hoffmann La Roche Castor wax-amprotropine-resin compositions
US3155590A (en) * 1962-08-02 1964-11-03 Ncr Co Encapsulation process and its product
US3499960A (en) * 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
US3594470A (en) * 1968-02-19 1971-07-20 Abbott Lab Chewable tablets including coated particles of pseudoephedrine-weak cation exchange resin
GB1218102A (en) * 1968-03-15 1971-01-06 Philips Nv Improvements in medicaments comprising drug/ion-exchange resin compounds
DE2246037B2 (en) * 1972-09-20 1975-02-27 Taeschner & Co, 8831 Kipfenberg Orally applicable drug with delayed absorption in suspension form
US4221728A (en) * 1977-12-28 1980-09-09 General Electric Company Stabilized polycarbonate compositions
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
JPS6045845B2 (en) * 1979-10-31 1985-10-12 田辺製薬株式会社 Method for producing microcapsules containing pharmaceutical substances
JPS57197214A (en) * 1981-05-29 1982-12-03 Tanabe Seiyaku Co Ltd Rapid-releasing microcapsule and its preparation
CA1236023A (en) * 1984-07-18 1988-05-03 Yegnaswami Raghunathan Controlled release pharmaceutical preparations
US4847077A (en) * 1984-07-18 1989-07-11 Pennwalt Corporation Controlled release pharmaceutical preparations
US4788055A (en) * 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
US4810501A (en) * 1986-06-17 1989-03-07 Warner-Lambert Company Sustained release pharmaceutical preparations
NZ219925A (en) * 1986-07-30 1989-06-28 Pennwalt Corp Polymer-treated sulphonic acid cationic exchange resin particles
IE62100B1 (en) * 1986-07-30 1994-12-14 Fisons Corp Coated ion exchange resins
US4894239A (en) * 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013798A1 (en) * 1993-11-18 1995-05-26 Cancer Research Institute Inc. Controlled release preparation
US5932248A (en) * 1993-11-18 1999-08-03 Paragon Medical Limited Controlled release preparations for cytotoxic or cytostatic drugs

Also Published As

Publication number Publication date
IE62765B1 (en) 1995-02-22
JPH02172912A (en) 1990-07-04
CA2001859A1 (en) 1990-04-02
IE893537L (en) 1990-05-02
NZ231229A (en) 1992-03-26
EP0367746A2 (en) 1990-05-09
DK546389A (en) 1990-05-03
DK175659B1 (en) 2005-01-10
US4996047A (en) 1991-02-26
PH26699A (en) 1992-09-14
AU638420B2 (en) 1993-07-01
DK546389D0 (en) 1989-11-02
DE68912882D1 (en) 1994-03-17
ATE101033T1 (en) 1994-02-15
DE68912882T2 (en) 1994-06-01
EP0367746A3 (en) 1991-01-23
CA2001859C (en) 1995-10-31
EP0367746B1 (en) 1994-02-02
JP2941314B2 (en) 1999-08-25

Similar Documents

Publication Publication Date Title
AU4430689A (en) Sustained release drug-resin complexes
AU7534087A (en) Sustained release pharmaceutical compositions in oral dosage form
AU6764390A (en) Pharmaceutical granules and drug dosage units made therefrom
PT754452E (en) PHARMACEUTICAL PREPARATIONS IN THE FORM OF LIBERTABLE COATED CAPSULES ON THE BOTTOM OF THE DIGESTIVE TRACT
AU619328B2 (en) Cytotoxic drug conjugates
AU2941489A (en) Reduction of side effects of cancer therapy
CA2149362A1 (en) Pharmaceutical composition based on guar gum coated with simethicone, inassociation with a neutralizing antacid
CA2232879A1 (en) Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
ATE202473T1 (en) RAPID-RELEASE TABLET CORE WITH INSOLUBLE MEDICINAL MEDICINAL AND WITH A RELEASE COATING
NL194781B (en) Pharmaceutical preparation for oral administration containing a cyclosporine.
NZ332299A (en) Oral sustained release containing a hydrophilic and hydrophobic layer especially for medicaments containing nifedipine
NO830948L (en) ORAL ADMINISTRATIVE PHARMACEUTICAL PREPARATIONS.
GEP20033014B (en) Enteric Coated Pharmaceutical Composition and Method of Manufacturing
CA2301503A1 (en) Pharmaceutical compositions for oral administration of molecular iodine
AU4121297A (en) Galenic form with extended release of milnacipran
AU619329B2 (en) Cytotoxic drug conjugates
ATE124255T1 (en) ORAL FORMULATIONS CONTAINING POLYPEPTIDES THAT DISBAVE IN THE LARGE INTESTINE.
MY107811A (en) Polyamine drug-resin complexes
EP0325270A3 (en) Anticancer conjugates
IE862199L (en) Drug particle
CA2234969A1 (en) Adhesive patch for lithium controlled release
GR900300082T1 (en) Use of dapiprazole for the manufacture of a pharmaceutical composition inhibiting the development of tolerance in the analgesic treatment with morphine
RU93043627A (en) PHARMACEUTICAL COMPOSITION, CONTAINING A COMPLEX OF RESIN AND POLYAMINIC DRUGS
AU1305999A (en) (+)-ephedrine as a sympathomimetic drug
EP0375649A3 (en) Swelling-controlled oral delivery system for drugs